231 related articles for article (PubMed ID: 15705654)
1. Estimating cancer survival and clinical outcome based on genetic tumor progression scores.
Rahnenführer J; Beerenwinkel N; Schulz WA; Hartmann C; von Deimling A; Wullich B; Lengauer T
Bioinformatics; 2005 May; 21(10):2438-46. PubMed ID: 15705654
[TBL] [Abstract][Full Text] [Related]
2. Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data.
Gui J; Li H
Bioinformatics; 2005 Jul; 21(13):3001-8. PubMed ID: 15814556
[TBL] [Abstract][Full Text] [Related]
3. Dimension reduction methods for microarrays with application to censored survival data.
Li L; Li H
Bioinformatics; 2004 Dec; 20(18):3406-12. PubMed ID: 15256406
[TBL] [Abstract][Full Text] [Related]
4. Partial Cox regression analysis for high-dimensional microarray gene expression data.
Li H; Gui J
Bioinformatics; 2004 Aug; 20 Suppl 1():i208-15. PubMed ID: 15262801
[TBL] [Abstract][Full Text] [Related]
5. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer.
Vis AN; Schröder FH; van der Kwast TH
Eur Urol; 2006 Aug; 50(2):258-65. PubMed ID: 16413660
[TBL] [Abstract][Full Text] [Related]
6. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
7. Bladder cancer stage and outcome by array-based comparative genomic hybridization.
Blaveri E; Brewer JL; Roydasgupta R; Fridlyand J; DeVries S; Koppie T; Pejavar S; Mehta K; Carroll P; Simko JP; Waldman FM
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7012-22. PubMed ID: 16203795
[TBL] [Abstract][Full Text] [Related]
8. Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations.
Verma M; Manne U
Crit Rev Oncol Hematol; 2006 Oct; 60(1):9-18. PubMed ID: 16829121
[TBL] [Abstract][Full Text] [Related]
9. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL
J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789
[TBL] [Abstract][Full Text] [Related]
10. Mtreemix: a software package for learning and using mixture models of mutagenetic trees.
Beerenwinkel N; Rahnenführer J; Kaiser R; Hoffmann D; Selbig J; Lengauer T
Bioinformatics; 2005 May; 21(9):2106-7. PubMed ID: 15657098
[TBL] [Abstract][Full Text] [Related]
11. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
12. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
Eggener SE; Roehl KA; Smith ND; Antenor JA; Han M; Catalona WJ
J Urol; 2005 Apr; 173(4):1150-5. PubMed ID: 15758725
[TBL] [Abstract][Full Text] [Related]
13. Radiation rescue for biochemical failure after surgery for prostate cancer: predictive parameters and an assessment of contemporary predictive models.
Symon Z; Kundel Y; Sadetzki S; Oberman B; Ramon J; Laufer M; Catane R; Pfeffer MR
Am J Clin Oncol; 2006 Oct; 29(5):446-50. PubMed ID: 17023777
[TBL] [Abstract][Full Text] [Related]
14. CANSURV: A Windows program for population-based cancer survival analysis.
Yu B; Tiwari RC; Cronin KA; McDonald C; Feuer EJ
Comput Methods Programs Biomed; 2005 Dec; 80(3):195-203. PubMed ID: 16257080
[TBL] [Abstract][Full Text] [Related]
15. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
16. The influence of HER2 genotypes as molecular markers in ovarian cancer outcome.
Pinto D; Pereira D; Portela C; da Silva JL; Lopes C; Medeiros R
Biochem Biophys Res Commun; 2005 Oct; 335(4):1173-8. PubMed ID: 16112085
[TBL] [Abstract][Full Text] [Related]
17. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
18. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy.
Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Blute ML
J Urol; 2008 Apr; 179(4):1354-60; discussion 1360-1. PubMed ID: 18289596
[TBL] [Abstract][Full Text] [Related]
19. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
[TBL] [Abstract][Full Text] [Related]
20. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
Mitchell JA; Cooperberg MR; Elkin EP; Lubeck DP; Mehta SS; Kane CJ; Carroll PR
J Urol; 2005 Apr; 173(4):1126-31. PubMed ID: 15758720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
